Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph Markowitz

Showing results (51-60 of 82) with videos related to

Pageof 9
Sort By:
Science Signaling|April 17, 2014
Intronic miR-3151 within BAALC drives leukemogenesis by deregulating the TP53 pathwayAnn-Kathrin Eisfeld, Sebastian Schwind, Ravi Patel, et al.
Cancer|March 4, 2023
Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patientsZeynep Eroglu, Shifra Krinshpun, Ekaterina Kalashnikova, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 12, 2022
Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33/CD3 T cell engager, ex vivo in MDS and melanomaPingyan Cheng, Xianghong Chen, Robert Dalton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2009
A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomasTanios Bekaii-Saab, Joseph Markowitz, Nichole Prescott, et al.
Scientific Reports|November 15, 2017
Nitric oxide mediated inhibition of antigen presentation from DCs to CD4<sup>+</sup> T cells in cancer and measurement of STAT1 nitrationJoseph Markowitz, Jiang Wang, Zach Vangundy, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 6, 2024
Patient reported outcomes and patient experiences of immune checkpoint modulators for advanced or recurrent melanoma: a mixed methods studyDanielle B Tometich, Carley Geiss, Melinda L Maconi, et al.
Scientific Reports|March 8, 2018
Author Correction: Nitric oxide mediated inhibition of antigen presentation from DCs to CD4<sup>+</sup> T cells in cancer and measurement of STAT1 nitrationJoseph Markowitz, Jiang Wang, Zach Vangundy, et al.
Frontiers in Immunology|March 13, 2020
Multi-Dimensional Flow Cytometry Analyses Reveal a Dichotomous Role for Nitric Oxide in Melanoma Patients Receiving ImmunotherapySaurabh K Garg, Matthew J Ott, A G M Mostofa, et al.
Biopolymers|May 20, 2014
Simultaneous inhibition of key growth pathways in melanoma cells and tumor regression by a designed bidentate constrained helical peptideAmlanjyoti Dhar, Shampa Mallick, Piya Ghosh, et al.
Frontiers in Oncology|March 20, 2018
Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic MelanomaJohn E Mullinax, MacLean Hall, Sangeetha Prabhakaran, et al.
Pageof 9

Showing results (51-60 of 82) with videos related to

Sort By:
Pageof 9
Science Signaling|April 17, 2014
Intronic miR-3151 within BAALC drives leukemogenesis by deregulating the TP53 pathwayAnn-Kathrin Eisfeld, Sebastian Schwind, Ravi Patel, et al.
Cancer|March 4, 2023
Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patientsZeynep Eroglu, Shifra Krinshpun, Ekaterina Kalashnikova, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 12, 2022
Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33/CD3 T cell engager, ex vivo in MDS and melanomaPingyan Cheng, Xianghong Chen, Robert Dalton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2009
A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomasTanios Bekaii-Saab, Joseph Markowitz, Nichole Prescott, et al.
Scientific Reports|November 15, 2017
Nitric oxide mediated inhibition of antigen presentation from DCs to CD4<sup>+</sup> T cells in cancer and measurement of STAT1 nitrationJoseph Markowitz, Jiang Wang, Zach Vangundy, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 6, 2024
Patient reported outcomes and patient experiences of immune checkpoint modulators for advanced or recurrent melanoma: a mixed methods studyDanielle B Tometich, Carley Geiss, Melinda L Maconi, et al.
Scientific Reports|March 8, 2018
Author Correction: Nitric oxide mediated inhibition of antigen presentation from DCs to CD4<sup>+</sup> T cells in cancer and measurement of STAT1 nitrationJoseph Markowitz, Jiang Wang, Zach Vangundy, et al.
Frontiers in Immunology|March 13, 2020
Multi-Dimensional Flow Cytometry Analyses Reveal a Dichotomous Role for Nitric Oxide in Melanoma Patients Receiving ImmunotherapySaurabh K Garg, Matthew J Ott, A G M Mostofa, et al.
Biopolymers|May 20, 2014
Simultaneous inhibition of key growth pathways in melanoma cells and tumor regression by a designed bidentate constrained helical peptideAmlanjyoti Dhar, Shampa Mallick, Piya Ghosh, et al.
Frontiers in Oncology|March 20, 2018
Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic MelanomaJohn E Mullinax, MacLean Hall, Sangeetha Prabhakaran, et al.
Pageof 9